Navigation Links
KaloBios to Present at Leerink Swann Rare Disease Roundtable
Date:9/30/2013

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at the Le Parker Meridien in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Company Presentation:
When: Wednesday, October 2, 2013, 10:30 AM EDT
Where: Le Parker Meridien, New York City, NY

Webcast:
To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://leerink.metameetings.com/webcasts/rdroundtable13/directlink?ticker=KBIO.

A replay of the webcast will be available one hour after the conclusion of the live event. 

About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Contact:

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates 
Tel:  (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com


'/>"/>
SOURCE KaloBios Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
8. KaloBios to Present at Needham Healthcare Conference
9. KaloBios Reports First Quarter 2013 Financial Results
10. KaloBios to Present at Stifel Healthcare Conference 2013
11. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... ... Six greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the ... of blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives ... to have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... (ISPE) will host its 2017 Process Validation and Process Validation Statistics ... comprehensive solutions to process validation lifecycle challenges faced by process validation professionals ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global ... in Jupiter. The state of the art center will provide advanced surgical ... a goal of providing heart patients longer lives. , North American Veterinary Heart ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... to announce the launch of their partnership to provide the Pharmacist eCare ... first pharmacy-focused platform in the country with the ability to develop the Pharmacist ...
Breaking Medicine News(10 mins):